| Online-Ressource |
Verfasst von: | Mussetti, Alberto [VerfasserIn]  |
| Kanate, Abraham S. [VerfasserIn]  |
| Wang, Tao [VerfasserIn]  |
| He, Meilun [VerfasserIn]  |
| Hamadani, Mehdi [VerfasserIn]  |
| Finel, Hervé [VerfasserIn]  |
| Boumendil, Ariane [VerfasserIn]  |
| Glass, Bertram [VerfasserIn]  |
| Castagna, Luca [VerfasserIn]  |
| Dominietto, Alida [VerfasserIn]  |
| McGuirk, Joseph [VerfasserIn]  |
| Blaise, Didier [VerfasserIn]  |
| Gülbas, Zafer [VerfasserIn]  |
| Diez-Martin, Jose [VerfasserIn]  |
| Marsh, Steven G. E. [VerfasserIn]  |
| Paczesny, Sophie [VerfasserIn]  |
| Gadalla, Shahinaz M. [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Zhang, Mei-Jie [VerfasserIn]  |
| Spellman, Stephen R. [VerfasserIn]  |
| Lee, Stephanie J. [VerfasserIn]  |
| Bolon, Yung-Tsi [VerfasserIn]  |
| Sureda, Anna [VerfasserIn]  |
Titel: | Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas |
Verf.angabe: | Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda |
E-Jahr: | 2023 |
Jahr: | 28 February 2023 |
Umfang: | 9 S. |
Fussnoten: | Online verfügbar 25. Dezember 2022, Artikelversion 28. Februar 2023 ; Gesehen am 11.07.2023 |
Titel Quelle: | Enthalten in: Transplantation and cellular therapy |
Ort Quelle: | [Amsterdam] : Elsevier B. V., 2021 |
Jahr Quelle: | 2023 |
Band/Heft Quelle: | 29(2023), 3 vom: Feb., Seite 184.e1-184.e9 |
ISSN Quelle: | 2666-6367 |
Abstract: | When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if both are available. In this study we wanted to test whether using a haploidentical donor has the same results of a MUD. A total of 2140 adults (34% Center for International Blood and Marrow Transplant Research, 66% European Society for Blood and Marrow Transplantation registry) aged ≥18 years who received their first haploidentical hematopoietic cell transplantation (haplo-HCT) or MUD-HCT (8/8 match at HLA-loci A, B, C, and DRB1) for lymphoma using PTCy-based GVHD prophylaxis from 2010 to 2019 were retrospectively analyzed. The majority of both MUD and haploidentical HCTs received reduced intensity/nonmyeloablative conditioning (74% and 77%, respectively) and used a peripheral blood stem cell graft (91% and 60%, respectively) and a 3-drug GVHD prophylaxis (PTCy + calcineurin inhibitor + MMF in 54% and 90%, respectively). Haploidentical HCT has less favorable results versus MUD cohort in terms of overall mortality (hazard ratio [HR= = 1.69; 95% confidence interval [CI], 1.30-2.27; P < .001), progression-free survival (HR=1.39; 95% CI, 1.10-1.79; P = .008), nonrelapse mortality (HR = 1.93; 95% CI, 1.21-3.07; P = .006), platelet engraftment (HR = 0.69; 95% CI, 0.59-0.80; P < .001), acute grade 2-4 GVHD incidence (HR = 1.65; 95% CI, 1.28-2.14; P < .001), and chronic GVHD (HR = 1.79; 95% CI, 1.30-2.48, P < .001). No significant differences were observed in terms of relapse and neutrophil engraftment. Adjusting for propensity score yielded similar results. Whenever MUD is available in a timely manner, it should be preferred over a haploidentical donor when using PTCy-based GVHD prophylaxis for patients with lymphoma. |
DOI: | doi:10.1016/j.jtct.2022.11.028 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.jtct.2022.11.028 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S2666636722018012 |
| DOI: https://doi.org/10.1016/j.jtct.2022.11.028 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Haploidentical donor |
| Lymphoma |
| Matched unrelated donor |
| Post-transplant cyclophosphamide |
K10plus-PPN: | 1852358416 |
Verknüpfungen: | → Zeitschrift |
Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas / Mussetti, Alberto [VerfasserIn]; 28 February 2023 (Online-Ressource)